Welcome to our dedicated page for Actinium Pharmaceuticals news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmaceuticals stock.
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) is a New York-based biopharmaceutical company focused on developing innovative targeted radiotherapies for the treatment of advanced cancers. Leveraging its proprietary delivery platform, Actinium utilizes alpha-emitting Actinium-225 and Bismuth-213, as well as certain beta-emitting radiopharmaceuticals, in conjunction with monoclonal antibodies to target and kill cancer cells. The company’s leading product candidate, Iomab™-B, is designed to prepare patients for hematopoietic stem cell transplants (bone marrow transplants) by delivering targeted radiotherapy directly to the bone marrow. Iomab™-B is currently in a pivotal, multicenter Phase 3 clinical study for refractory and relapsed acute myeloid leukemia (AML) patients over the age of 55, focusing on durable complete remission as its primary endpoint.
Actinium's second key program, Actimab-A, is undergoing clinical development in Phase 1/2 trials for newly diagnosed AML patients. This program utilizes Actinium-225 and aims to improve outcomes for patients who have failed existing therapies. Actinium is also involved in numerous partnerships and collaborations, such as with Astellas Pharma, AVEO Oncology/LG Chem Life Sciences, and others, to expand its reach in the realm of radiotherapy for solid tumors.
The company has demonstrated promising results in various studies, including the Phase 3 SIERRA trial for Iomab™-B, which showed significant improvements in survival rates among high-risk AML patients, particularly those with TP53 mutations. Further, Actinium's proprietary cyclotron technology for producing Actinium-225 at commercial scale holds potential for reducing production costs and enhancing supply for clinical and commercial purposes. With a robust pipeline and a strong patent portfolio comprising over 230 patents and applications, Actinium Pharmaceuticals continues to make strides in the field of targeted radiotherapies.
For more information, visit Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced that two abstracts on targeted radiotherapies combined with CD47 antibody immunotherapy will be presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) from November 12-14, 2021. The titles focus on enhancing anti-tumor effects in solid tumors and acute myeloid leukemia. CEO Sandesh Seth expressed excitement about the R&D advancements and the company's efforts in the immunotherapy field. Full posters will be available on Actinium's website on November 9, 2021.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021. The company's presentation is scheduled for September 29 at 3:20 p.m. ET. Attendees can access the webcast via Actinium's investor relations website. Actinium focuses on developing targeted radiotherapies, particularly Antibody Radiation-Conjugates, aimed at improving treatment outcomes for cancer patients with high unmet needs. The company's lead candidate is I-131 apamistamab (Iomab-B), being studied in pivotal trials.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced several key senior leadership appointments aimed at advancing its growth strategy. Arun Swaminathan, Ph.D., has been appointed as Chief Business and Commercial Officer, while Paul Diamond, Ph.D., joins as Vice President, Patent and Legal Counsel. Avinash Desai, M.D., has been promoted to Chief Medical Officer. These leaders together bring over 50 years of experience in biopharmaceuticals, enhancing Actinium's focus on its pipeline, particularly the recently completed Phase 3 SIERRA trial for Iomab-B.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced its participation in four upcoming investor conferences, highlighting its pivotal Phase 3 trial for Iomab-B and upcoming milestones from its targeted radiotherapy pipeline. The conferences are scheduled from September 27 to October 13, 2021. CEO Sandesh Seth emphasized the strong momentum as the company approaches significant data updates in the fourth quarter. Actinium specializes in targeted radiotherapies aimed at treating patients with unmet needs, focusing on improving outcomes through innovative therapies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has completed enrollment in the pivotal Phase 3 SIERRA trial for Iomab-B, aimed at treating patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial, involving 150 patients across 24 centers in the U.S. and Canada, assesses the efficacy of Iomab-B in providing Bone Marrow Transplant (BMT) access. Actinium plans to present data updates in Q4 2021 and topline results in mid-2022 to support a Biologics License Application (BLA) for Iomab-B.
Actinium Pharmaceuticals (NYSE: ATNM) announced its inclusion in the Russell Microcap® Index effective June 28, 2021. This membership, determined by market-cap rankings, will last for one year and grants Actinium access to associated growth and value style indexes. The Russell indexes are critical benchmarks for investment managers, with approximately $10.6 trillion in assets linked to them. As a clinical-stage biopharmaceutical company, Actinium focuses on developing innovative therapies, notably its lead candidate I-131 apamistamab, which is under study for conditioning before bone marrow transplants.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced the enhancement of its intellectual property portfolio for its lead candidate, Iomab-B, with patents granted in the EU and Japan. These patents, covering the composition and administration methods of Iomab-B, are expected to be valid through 2036 and 2037. Actinium aims to leverage its patents for aggressive development in targeted conditioning, particularly for bone marrow transplants and cell therapies. The company holds multiple patents globally and enjoys orphan drug designation for Iomab-B, potentially providing market exclusivity.
Actinium Pharmaceuticals (NYSE: ATNM) presented promising data from its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 SNMMI Annual Meeting. Iomab-B, a radiotherapy targeting CD45, aims to enable potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial showed a remarkable 100% BMT and engraftment rate in the Iomab-B group, while only 18% in the control arm. With 75% patient enrollment completed, the results highlight Iomab-B's potential to transform treatment outcomes in this challenging patient population.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented safety data from the Phase 3 SIERRA trial of Iomab-B for relapsed or refractory Acute Myeloid Leukemia at the 2021 SNMMI Annual Meeting. The study involved 113 patients, demonstrating lower rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Iomab-B's targeted delivery system aims to minimize side effects while preparing patients for bone marrow transplants. With 75% enrollment complete, Actinium anticipates further data presentations in the future.
FAQ
What is the current stock price of Actinium Pharmaceuticals (ATNM)?
What is the market cap of Actinium Pharmaceuticals (ATNM)?
What is Actinium Pharmaceuticals' primary focus?
What are the main product candidates of Actinium Pharmaceuticals?
What is unique about Actinium's delivery platform?
What are the recent achievements of Actinium Pharmaceuticals?
Who are some of Actinium Pharmaceuticals' key partners?
What are the benefits of Actinium's cyclotron technology?
What is Iomab™-B used for?
What is the significance of the SIERRA trial?
How extensive is Actinium's patent portfolio?
Where can I find more information about Actinium Pharmaceuticals?
